A Phase 2/3 interventional study of ATV and DRV in Acquired Immune Deficiency Syndrome (AIDS) and HIV Infections, sponsored by Gilead Sciences. Active, not recruiting at 23 sites in 7 countries. Open to participants aged 4 Weeks to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing atazanavir in Acquired Immunodeficiency Syndrome — none open to participants now, 1 under way, 1 of them phase 3. atazanavir · Acquired Immunodeficiency Syndrome.
Among the 20 studies testing atazanavir in Acquired Immunodeficiency Syndrome, this one is the 7th largest by enrollment, is one of 2 that started in 2014, is the only one in phase 2/3, and was the 20th registered.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →None of the 20 studies testing atazanavir in Acquired Immunodeficiency Syndrome is open now. The open studies under Acquired Immunodeficiency Syndrome, anywhere →
atazanavir: first FDA approval 2003 (REYATAZ), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 4 Weeks to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5 · Phase 4 10
First in 2004; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 133 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 63 across the 20 interventional studies. Of the 19 that completed or were terminated, 14 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 20 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences: none open now, 1 under way, 1 of them phase 3. Of 34 finished, 19 (56%) have results posted.
Among the 35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences, this one is the 15th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2014, is one of 4 in phase 2/3, and was the 34th registered.
Gilead Sciences’s Acquired Immunodeficiency Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing atazanavir in Acquired Immunodeficiency Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 35 in Acquired Immunodeficiency Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to learn more about the safety and dosing of study drugs, cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted darunavir (DRV/co) and emtricitabine/tenofovir alafenamide (F/TAF), in children (age ≥ 4 weeks to \< 18 years) with HIV.
Key Inclusion Criteria:
Stable antiretroviral (ARV) regimen for a minimum of 3 months prior to the screening visit.
Participants enrolled after the implementation of Amendment 9:
Documented plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) for ≥ 3 months preceding the screening visit:
Participants enrolled after the implementation of Amendment 9:
Adequate renal function: Estimated (eGFR) ≥ 90 mL/min/1.73m2 using the Schwartz formula. If ≥ 1 year old, eGFR greater than or equal to the minimum normal value for age using the Schwartz formula. If \< 1 year old as follows:
Note: Other protocol defined Inclusion/Exclusion criteria do apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants ages 12 to \<18 years old will receive cobicistat 150 mg with either ATV or DRV plus background regimen (BR). The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.
Drug: ATV · Drug: DRV · Drug: Cobicistat · Drug: BR
Participants aged 6 to \<12 years old and ≥25 to \<40kg will receive cobicistat 150 mg and F/TAF 200/25 mg with either ATV or DRV.
Drug: ATV · Drug: DRV · Drug: Cobicistat · Drug: F/TAF
Participants age ≥ 2 years old will receive cobicistat 90 mg and F/TAF 120/15 mg with either ATV or DRV.
Drug: ATV · Drug: DRV · Drug: Cobicistat · Drug: F/TAF
Participants age ≥ 4 weeks old weighing 14 to \< 25 kg will receive cobicistat tablet for oral suspension (TOS) 90 mg, once daily and F/TAF TOS 120/15 mg, once daily with either ATV or DRV or lopinavir boosted by ritonavir (LPV/r). Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, minimum age and weight for DRV is ≥ 3 years and ≥ 15 kg; participants receiving LPV/r will not receive cobicistat TOS.
Drug: ATV · Drug: DRV · Drug: LPV/r · Drug: Cobicistat TOS · Drug: F/TAF TOS
Participants age ≥ 4 weeks old weighing 10 to \< 14 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 60/7.5 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.
Drug: ATV · Drug: LPV/r · Drug: Cobicistat TOS · Drug: F/TAF TOS
Participants age ≥ 4 weeks old weighing 6 to \< 10 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 30/3.75 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.
Drug: ATV · Drug: LPV/r · Drug: Cobicistat TOS · Drug: F/TAF TOS
Participants age ≥ 4 weeks old weighing 3 to \< 6 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 15/1.88 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.
Drug: ATV · Drug: LPV/r · Drug: Cobicistat TOS · Drug: F/TAF TOS
Participants ages ≥ 4 weeks old weighing ≥ 10 to \< 14 kg will receive F/TAF TOS 60/7.5 mg, once daily with the third unboosted drug.
Drug: Third Unboosted Drug · Drug: F/TAF TOS
Participants ages ≥ 4 weeks old weighing ≥ 6 to \< 10 kg will receive F/TAF TOS 30/3.75 mg, once daily with the third unboosted drug.
Drug: Third Unboosted Drug · Drug: F/TAF TOS
Participants ages ≥ 4 weeks old weighing ≥ 3 to \< 6 kg will receive F/TAF TOS 15/1.88 mg, once daily with the third unboosted drug.
Drug: Third Unboosted Drug · Drug: F/TAF TOS
Capsules administered once daily according to dosing recommendations per product monograph
Also known as: Reyataz®
Tablets administered once daily according to dosing recommendations per product monograph
Also known as: Prezista®
Tablets administered orally once daily with food
Also known as: GS-9350, Tybost®
Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).
Drug pages: Emtricitabine · Tenofovir alafenamide
Tablets administered orally once daily
Also known as: Descovy®
Drug pages: Lopinavir · Ritonavir
Solution administered orally
ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
Tablets for oral suspension
Also known as: GS-9350, Tybost®
Drug page: Emtricitabine tenofovir alafenamide
Tablets for oral suspension
Also known as: Descovy®
Pharmacokinetic (PK) Parameter: AUCtau of ATV, DRV, TAF, and TFV
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). AUCtau for ATV (Cohorts 1 Part A, 2, 3, and 4 \[Groups 2 to 4\]); DRV (Cohorts 1 Part A, 2, and 3); TAF (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 \[Groups 1 to 3\] taking F/TAF); and TFV (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 \[Groups 1 to 3\] taking F/TAF) will be reported.
Time frame: Predose on Day 1, and postdose up to Week 48
Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) Through Week 24
Time frame: First dose date up to Week 24 plus 30 days (Cumulative data through Week 24)
Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities Through Week 24
Time frame: First dose date up to Week 24 plus 30 days (Cumulative data through Week 24)
PK Parameter: Ctau of ATV, DRV, COBI, FTC and TFV
Ctau is defined as the observed drug concentration at the end of the dosing interval. Ctau for ATV (cohorts 1, 2, 3, and 4 (Groups 2 to 4)), DRV (cohorts 1, 2, and 3), COBI (except Cohort 5), FTC and TFV (cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.
Time frame: Predose on Day 1, and postdose up to Week 48
PK Parameter: Cmax of ATV, DRV, COBI, TAF, FTC and TFV
Cmax is defined as the maximum observed concentration of drug. Cmax for ATV (Cohorts 1, 2, 3, and 4 \[Groups 2 to 4\]) and DRV (Cohorts 1, 2, and 3); for COBI (except Cohort 5); for TAF, FTC and TFV (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.
Time frame: Predose on Day 1, and postdose up to Week 48
PK Parameter: CL/F of ATV, DRV, COBI, TAF, FTC and TFV
CL/F is defined as the apparent oral clearance following administration of the drug. CL/F for ATV (Cohorts 1, 2, 3, and 4 \[Groups 2 to 4\]) and DRV (Cohorts 1, 2, and 3); for COBI (except Cohort 5); for TAF, FTC and TFV (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.
Time frame: Predose on Day 1, and postdose up to Week 48
PK Parameter: Vz/F of COBI, TAF, FTC and TFV
Vz/F is defined as the apparent volume of distribution of the drug. Vz/F for COBI (Except Cohort 5); for TAF (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF); for FTC and TFV (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.
Time frame: Predose on Day 1, and postdose up to Week 48
PK Parameter: AUCtau of COBI and FTC
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). AUCtau for COBI (Except Cohort 5) and FTC will be reported.
Time frame: Predose on Day 1, and postdose up to Week 48
PK Parameter: AUClast of TAF, FTC and TFV
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. AUClast for TAF (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF); for FTC and TFV (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.
Time frame: Predose on Day 1, and postdose up to Week 48
PK Parameter: Clast of TAF
Clast is defined as the the last observed quantifiable concentration of the drug in plasma. Clast for TAF (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.
Time frame: Predose on Day 1, and postdose up to Week 48
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Time frame: First dose date up to Week 48 plus 30 days (Cumulative data through Week 48)
Percentage of Participants Experiencing Clinically Significant Changes in Safety Laboratory Values
Time frame: First dose date up to Week 48 plus 30 days (Cumulative data through Week 48)
Percentage of Participants with HIV-1 RNA < 50 Copies/mL at Week 24 and as Defined by the US FDA-defined Snapshot Algorithm
Time frame: Week 24
Percentage of Participants with HIV-1 RNA < 50 Copies/mL at Week 48 and as Defined by the US FDA-defined Snapshot Algorithm
Time frame: Week 48
Change from Baseline in CD4+ Cell Counts (cells/μL) at Week 24
Time frame: Baseline, Week 24
Change from Baseline in CD4+ Cell Counts (cells/μL) at Week 48
Time frame: Baseline, Week 48
Change from Baseline in Percentage of CD4+ Cells at Week 24
Time frame: Baseline, Week 24
Change from Baseline in Percentage of CD4+ Cells at Week 48
Time frame: Baseline, Week 48
Acceptability of COBI and F/TAF as Measured by Palatability Score
Time frame: Week 48
Ran from Jan 2014 to primary completion in Jun 2025, 136 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atazanavir · Darunavir · Cobicistat · Emtricitabine · Tenofovir alafenamide · Emtricitabine tenofovir alafenamide
Acquired Immunodeficiency Syndrome →